Healthcare products brand Johnson & Johnson claims that it wants to buy breast-implant manufacturer Mentor Corp. for $1.07 billion to establish Johnson & Johnson in the cosmetic and reconstructive medicine industry.

If the acquisition pushes through, Johnson & Johnson will not only be getting products for breast implants, the company a Botox alternative. According to reports, California-based Mentor Corp. is amidst an extensive research to develop a drug that will compete against Botox. 

Mentor’s “PurTox” drug has currently completed three Phase 3 clinical trials. Phase 3 is the final level of trials before submitting its pending approval from the US Food and Drug Administration.

According to the Capital Times, “The development of PurTox stems from Mentor's 2003 deal for an exclusive license from the Wisconsin Alumni Research Foundation for botulinum toxin technology developed at the University of Wisconsin-Madison.”